Autolus Therapeutics
AUTL
50 hedge funds and large institutions have $230M invested in Autolus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 8 closing their positions.
134% more capital invested
Capital invested by funds: $98.4M → $230M (+$131M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 51 → 50 (-1)
3.8% less ownership
Funds ownership: 31.23% → 27.43% (-3.8%)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.65M |
| 2 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$1.86M |
| 3 |
BlackRock
New York
|
+$1.37M |
| 4 |
Morgan Stanley
New York
|
+$1M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$665K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$6.39M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.23M |
| 3 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$4.13M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$3.43M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.73M |
AUTL Hedge Fund Activity: Q2 2020 in Review
50 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2020, worth a combined $230M — up 134% from $98.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AUTL and 7 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 13 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.65M. The largest seller was Victory Capital Management, cutting an estimated $6.39M.
- 50 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2020, down from 51 in Q1 2020.
- Funds reported $230M of Autolus Therapeutics stock for Q2 2020, up 134% quarter-over-quarter.
- 7 funds opened new Autolus Therapeutics positions in Q2 2020 and 8 closed out, a net change of -1 holder.
- The largest Autolus Therapeutics buyer in Q2 2020 was Baker Bros. Advisors, an estimated $3.65M added.
- The largest Autolus Therapeutics seller in Q2 2020 was Victory Capital Management, an estimated $6.39M sold.
Based on aggregated 13F filings for Q2 2020.